{"id":"NCT00983073","sponsor":"Gr√ºnenthal GmbH","briefTitle":"Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking Either WHO Step I or Step II Analgesics or no Regular Analgesic","officialTitle":"An Evaluation of the Effectiveness and Tolerability of Tapentadol Hydrochloride Prolonged Release, and Tapentadol Hydrochloride Immediate Release on Demand, in Subjects With Uncontrolled Severe Chronic Pain Due to Osteoarthritis of the Knee Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09","primaryCompletion":"2010-06","completion":"2010-09","firstPosted":"2009-09-23","resultsPosted":"2012-03-29","lastUpdate":"2019-10-21"},"enrollment":224,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Pain","Osteoarthritis"],"interventions":[{"type":"DRUG","name":"Tapentadol","otherNames":["Nucynta","Palexia"]}],"arms":[{"label":"Tapentadol","type":"EXPERIMENTAL"}],"summary":"The main objective of the study is to evaluate the effectiveness, tolerability, and safety of tapentadol hydrochloride prolonged release in participants suffering from severe chronic pain due to osteoarthritis of the knee who are taking either WHO Step I or Step II analgesics or no regular analgesics. This is a clinical effectiveness trial designed to establish a link between anticipated clinical outcomes and the clinical practice by means of selected measures of clinical and subject-reported outcome.\n\nThe trial will compare the effectiveness of previous analgesic treatment (either WHO Step I or Step II analgesics or no regular analgesics) with that of tapentadol hydrochloride prolonged release (PR) treatment during defined periods of evaluation.","primaryOutcome":{"measure":"The Primary Endpoint is Defined as the Change From Week -1 of the Average Pain Intensity Score on an 11-point NRS-3 at Week 6.","timeFrame":"Baseline to end of week 6","effectByArm":[{"arm":"Tapentadol PR","deltaMin":-3.4,"sd":2.1}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":null},"locations":{"siteCount":24,"countries":["France","Germany","Poland","Spain","United Kingdom"]},"refs":{"pmids":["22792000"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":200},"commonTop":["Nausea","Dizziness","Constipation","Fatigue","Dry Mouth"]}}